SFX by Ex Libris Inc.

Title:	Polyglutamine diseases
Source:	Trends in Genetics [0168-9525] Hafezparast, Majid yr:1999

Basic

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Ellerby, Lisa M. "Kennedy's Disease." Journal of neurochemistry 72.1 (1999): 185-195.
description	2.	Orr, Harry T. "Are polyglutamine diseases expanding?" Neuron 70.3 (2011): 377-8.
description	3.	Greensmith, L. "Amyotrophic lateral sclerosis: recent advances and future therapies." Current opinion in neurology 18.6 (2005): 712-9.
description	4.	Lanka, V. "Arimoclomol: a potential therapy under development for ALS." Expert Opinion on Investigational Drugs 18.12 (2009): 1907-1918.
description	5.	Fischbeck, K H H. "Kennedy's disease." Neurology 43.11 (1993): 2424-5.
description	6.	Massman, P J J. "Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis." Journal of neurology, neurosurgery and psychiatry 61.5 (1996): 450-5.
description	7.	Au, K. "Kennedy's disease." Hong Kong medical journal 9.3 (2003): 217-220.
description	8.	Kobayashi, Y. "Caspase-3 Cleaves the Expanded Androgen Receptor Protein of Spinal and Bulbar Muscular Atrophy in a Polyglutamine Repeat Length-Dependent Manner." Biochemical and biophysical research communications 252.1 (1998): 145-150.
description	9.	Echeverria, Gloria V. "RNA-binding proteins in microsatellite expansion disorders: Mediators of RNA toxicity." Brain research 1462 (2012): 100-111.
description	10.	Li, H. "How do barrels form in somatosensory cortex?" Annals of the New York Academy of Sciences 1225.1 (2011): 119-129.
description	11.	Miller, G. "Could they all be prion diseases?" Science 326.5958 (2009): 1337-1339.
description	12.	DePaul, R. "Multiple orofacial indices in amyotrophic lateral sclerosis." Journal of speech and hearing research 36.6 (1994): 1158-67.
description	13.	Bruijn, Lucie I I. "Unraveling themechanisms involved in motor neuron degeneration in ALS." Annual Review of Neuroscience 27.1: 723-749.
description	14.	Valente, Enza Maria M. "Hereditary early-onset Parkinson's disease caused by mutations in PINK1." Science 304.5674 (2004): 1158-60.
description	15.	Kam, P C A A. "Anabolic steroid abuse: physiological and anaesthetic considerations." Anaesthesia 60.7 (2005): 685-692.
description	16.	Boillée, S. "ALS: a disease of motor neurons and their nonneuronal neighbors." Neuron 52.1 (2006): 39-59.
description	17.	Brown, Robert H. "Molecular biology of amyotrophic lateral sclerosis: insights from genetics." Nature reviews. Neuroscience 7.9 (2006): 710-23.
description	18.	Maravelias, C., C.. "Adverse effects of anabolic steroids in athletes: A constant threat." Toxicology letters 158.3 (2005): 167-175.
description	19.	Kalmar, B. "Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS." Journal of neurochemistry 107.2 (2008): 339-350.
description	20.	Kalmar, B. "Molecular chaperones as therapeutic targets in amyotrophic lateral sclerosis." Biochemical society transactions 33.4 (2005): 551-552.